Table 3.
Cox hazard regression analysis of the independent progression-free survival (PFS) predictors.
| P value | HR∗ | 95% CI∗∗ | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Age (≥55 years) | 0.719 | 1.024 | 0.647 | 1.622 |
| Sex (male) | 0.647 | 0.982 | 0.774 | 1.237 |
| Advanced disease stage (III–IV) | 0.037 | 2.614 | 1.102 | 7.524 |
| Prior adjuvant therapy | 0.037 | 0.892 | 0.481 | 0.994 |
| Lymph node metastasis | 0.018 | 3.664 | 1.187 | 8.650 |
| Bone metastasis | 0.036 | 2.790 | 1.073 | 8.221 |
| Number of metastatic sites (>2) | 0.020 | 1.723 | 1.089 | 2.727 |
| Duration since diagnosis (>30 months) | 0.442 | 1.187 | 0.767 | 1.837 |
| Neutropenia after first cycle of FTD/TPI | 0.041 | 0.738 | 0.425 | 0.924 |
| Baseline absolute eosinophil count | 0.022 | 2.089 | 1.027 | 4.910 |
| Number of FTD/TPI cycles | 0.006 | 0.899 | 0.833 | 0.969 |
∗HR: hazard ratio; ∗∗CI: confidence interval; FTD/TPI: trifluridine/tipiracil.